Antibody Approved Licensing Benchmarks
Deal economics across 31 transactions with 13 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$2.9B
13 deals with terms
Median Total Value
$3.0B
Upfront + milestones
Royalty Range
5.5%--11.5%
Average low--high
Deal Count
31
2017--2026
The median upfront payment for approved antibody licensing deals is $2.9B, based on 13 deals with disclosed terms from 2017--2026. Total deal values (including milestones) reach a median of $3.0B. Royalty rates typically range from 5.5% to 11.5%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Ablynx | Sanofi | 2018 | $4.8B | $4.8B |
| Provention Bio | Sanofi | 2023 | $2.9B | $2.9B |
| Recordati (Enjaymo) | Sanofi | 2024 | $825M | $825M |
Full antibody Approved Comp Set
Get the complete analysis -- 13 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific antibody asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2017--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.